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Abstract 
Nitric oxide (NO), an important signalling molecule, is synthesized from L-arginine by three 
isoforms of NO-synthase (NOS). Its overproduction has been associated with neurodegenerative 
disorders. Therefore, developing selective inhibitors of iNOS or nNOS is of great interest for 
decoding neurodestructive key factors. Suitable 18F-labelled analogues would allow for 
investigation of the NOS-function by molecular in vivo imaging with positron-emission-tomography. 
Potentially, the highly selective nNOS inhibitor 6-((3-((3-fluorophenyl-ethylamino)methyl)phenoxy)-
methyl)-4-methyl-pyridine-2-amine (1) is a suitable compound for labelling with no-carrier-added 
(n.c.a.) [18F]fluoride, complementing the established iNOS inhibitor 6-(2-[18F]fluoropropyl)-4-
methylpyridine-2-amine. 
 
 
 
Presently the radioorganic syntheses of n.c.a. 18F-labelled products are practically limited to 
nucleophilic procedures. Based on cyclic voltammetric measurements an electrochemical 
synthesis of n.c.a. N-[18F]fluorobis(trifluoromethylsulfonyl)imide (Tf2N-[
18F]F) was attempted. The 
following conversion of the electrosynthetic product with an activated arene led to an  
18F-labelled derivative. In this early developmental stage, a production of an n.c.a. electrophilic 18F-
fluorinating reagent from [18F]fluoride appears probable. For the effective labelling of NOS-
inhibitors, however more sophisticated labelling methods had to be chosen. 
With regard to the nNOS-Inhibitor [18F]1 a built-up radiosynthesis based on a iodonium ylide 2 as 
precursor was attempted. The activated aromatic system was efficiently and regionselectively 
labelled with n.c.a. [18F]fluoride in 79 % radiochemical yield (RCY). After conversion by reductive 
amination and microwave assisted displacement of the protecting groups the desired nNOS 
inhibitor was obtained in 15 % RCY. Alternatively, for a simplified late-stage 18F-labelling procedure 
the corresponding boronic ester precursor 3 was synthesized and labelled starting by novel 
copper(II) mediated n.c.a. 18F-fluorination and led to the same RCY. 
After optimizing the radiolabelling procedure of the established iNOS inhibitor  
6-(2-[18F]Fluorpropyl)-4-methylpyridin-2-amin, now there are two highly selective NOS-inhibitors 
available for preclinical in vivo evaluation studies. 
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